Journal: Drug Invention Today

Article Id: JPRS-Pcol-00004468
Title: Correction of asymmetric dimethylarginine-like pre-eclampsia in rats by micronized purified flavonoids fraction
Category: Pharmacology
Section: Research Article
  • Abstract
  • Audio Abstract
  • Authors
  • Pdf File
  • Citation
  • My Reference
  • Methodology
  • Abstract

    Background: About 10% of pregnancies in the world are accompanied by hypertensive disorders, while from 2% to 8% are pre-eclampsia. One of the components of the pathogenesis of pre-eclampsia is placental ischemia. The humoral factors released during it have a pro-inflammatory effect and can contribute to the development of endothelial dysfunction. One of the possible options for reducing the effects of these cytokines may be the use of drugs containing natural flavonoids, one of the positive aspects of which is the reduction of vein-specific inflammation. The Aim of the Study: This study aims to study the effectiveness of using purified micronized flavonoid fraction (diosmin+flavonoids expressed as hesperidin) in the correction of functional disorders that occur during pre-eclampsia in the experiment. Materials and Methods: The experiment was performed on 150 white female rats of the Wistar line weighing 250–300 g. Asymmetric dimethylarginine (ADMA)-like agent (N-nitro-L-arginine methyl ester) was introduced intraperitoneally at a dose of 25 mg/kg/day from 14 to 20 days of gestation. The purified micronized flavonoid fraction (diosmin+flavonoids expressed as hesperidin) in dosages of 86 mg/kg and 260 mg/kg was administered orally once a day from 14 to 20 days of pregnancy. On 21 days of pregnancy, functional tests and laboratory tests were performed. Results: The administration of purified micronized flavonoid fraction to laboratory animals leads to a pronounced correction of pathological changes in experimental ADMA-like pre-eclampsia with the greatest effect in a higher dose of the drug used. A significant decrease in systolic and diastolic pressure was noted, respectively, improved microcirculation in the placenta, restoration of the nitric oxide synthesizing function of the endothelium, and a decrease in proteinuria. Conclusion: The results of the study indicate the promise of using a purified micronized flavonoid fraction for the correction of functional changes in pre-eclampsia and substantiate the feasibility of further research in this direction.

  • Abstract Audio

    No Audio file found

  • About the authors and Affiliations

    Author(s) Name:

    Oksana E. Antsiferova, Alesya V. Yurakova*, Yuliya S. Lukyanova, Vladimir V. Gureev, Mikhail V. Korokin, Anastasia V. Gureeva, Tatyana G. Pokrovskaya, Oleg S. Gudyrev

    Affiliation(s) Name:

    Department of  Pharmacology and Clinical Pharmacology, Institute of Medicine, Belgorod State University, 85 Pobedy St., Belgorod 308015, Russia

    *Corresponding author: Alesya V. Yurakova, Department of Pharmacology and Clinical Pharmacology, Institute of Medicine, Belgorod State University, 85 Pobedy St., Belgorod 308015, Russia.

  • View Article File in pdf format.

    Article File
  • View Article Citation Here.

    0 View More
  • How to Cite my Article.

    Author:

    Oksana E. Antsiferova, Alesya V. Yurakova*, Yuliya S. Lukyanova, Vladimir V. Gureev, Mikhail V. Korokin, Anastasia V. Gureeva, Tatyana G. Pokrovskaya, Oleg S. Gudyrev

    Title:Correction of asymmetric dimethylarginine-like pre-eclampsia in rats by micronized purified flavonoids fraction
    Journal:Drug Invention Today
    Vol(issue):12 (November )
    Year:2019
    Page No: (2709-2712)
  • Experimental Methods Keywords

    Methodology:Endothelial dysfunction, Microcirculation, Pre-eclampsia, Proteinuria, Purified micronized flavonoid fraction, Rats
    Research Materials: flavonoid fraction (diosmin+flavonoids expressed as hesperidin)

Keywords

Endothelial dysfunction Microcirculation Pre-eclampsia Proteinuria Purified micronized flavonoid fraction Rats

Our Services

Most Downloaded List